text size  A   A

Rx Pharmaceutical Products

BEPREVE (bepotastine besilate ophthalmic solution) 1.5%

BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is a prescription eye drop that relieves itching associated with allergic conjunctivitis. BEPREVE works on 2 primary components of the allergic process that cause the development of allergy symptoms in the eye:

  • BEPREVE works by blocking the action of histamine—a substance your body produces when it detects an allergen. The release of histamine triggers an allergic cascade that results in itchy eyes and other common allergy symptoms.3
  • BEPREVE also stabilizes mast cells1 that release histamine and other chemicals that cause symptoms such as itching.

bepreve-bottle-packaging

Clinical studies show that 95% of BEPREVE-treated eyes had a clinically significant reduction of itching within minutes after a single drop of BEPREVE. Relief continued for up to 8 hours after dosing.4 Those studies also show that in 68% of eyes with severe itching, BEPREVE provided complete relief in minutes.5

BEPREVE is used twice a day.

Safety

The safety of BEPREVE was evaluated in a clinical study of 861 healthy subjects over a period of 6 weeks.1 BEPREVE was shown to be comfortable in the eye,3 and can be used in patients as young as 2 years of age.1

Directions for Use

Easy for patients to use; one drop in the morning, one drop in the evening.

Download dosing information plus step-by-step drop installation instructions for your patients.

Important Risk Information

  • BEPREVE is contraindicated in patients with a history of hypersensitivity reactions to bepotastine or any of the other ingredients.
  • BEPREVE is for topical ophthalmic use only.
  • To minimize risk of contamination, do not touch the dropper tip to any surface. Keep the bottle closed when not in use.
  • BEPREVE should not be used to treat contact lens-related irritation. Remove contact lenses prior to instillation of BEPREVE.
  • The most common adverse reaction occurring in approximately 25% of patients was a mild taste following instillation. Other adverse reactions occurring in 2%-5% of patients were eye irritation, headache, and nasopharyngitis.

Please click here to view the BEPREVE full Prescribing Information.

1. BEPREVE [package insert].
2. Allergic conjunctivitis. Merck Manual Web site. http://www.merckmanuals.com/home/print/sec20/ch226/ch226d.html. Accessed June 14, 2011.
3 Allergic reactions. Discovery Health Web site. http://science.howstuffworks.com/environmental/life/human-biology/allergy2.htm/printable. Accessed September 7, 2011.
4. Williams JI, Schooley GL,Gow JA, McNamara TR. Bepreve™ 1.5% provides clinically meaningful reduction in allergen-induced ocular itching for subjects in an analysis of two phase 3 conjunctival allergen challenge (CAC) clinical trials [AAAAI abstract 151]. J Allergy Clin Immunol. 2010;125(2)(suppl 1):AB38.
5. Clark JC, Williams JI, Gow JA, Abelson MB, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group. Bepotastine besilate ophthalmic solution 1.5% rapidly eliminates ocular itching in more severely allergic subjects in the conjunctival allergen challenge model of allergic conjunctivitis. Poster presented at: Eastern Allergy Conference; May 6-9, 2010; Palm Beach, FL. 6. Williams JI, Schooley GL, Gow JA, et al. Bepreve™ 1.5% provides clinically meaningful reduction in allergen-induced ocular itching for subjects in all analysis of two phase 3 conjunctival allergen challenge (CAC) clinical trials. Poster presented at: American Academy of Allergy, Asthma, and Immunology Annual Meeting 2010; February 26-March 2, 2010; New Orleans, LA

US/LGX/12/0052(1)